Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Ascari
Observed name:
S. Ascari
Institutions:
Humanitas University,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
IRCCS Humanitas Research Hospital,
University of Bologna
Observed institutions:
University of Modena and Reggio Emilia,
Humanitas University,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
IRCCS Humanitas Research Hospital,
University of Bologna
ORCID:
0009-0008-9317-9746
Observed ORCID:
0009-0008-9317-9746
OpenAlex ID:
A5113000708
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study
2023
·
Erica Villa
, Rossella Donghia
, et al.
·
Hepatology Communications
·
19
Advancements in immunotherapy for hepatocellular carcinoma
2025
·
Sara Ascari
, Rusi Chen
, et al.
·
Expert Review of Anticancer Therapy
·
9
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials
2026
·
Sara Ascari
, Rusi Chen
, et al.
·
World Journal of Gastroenterology
·
6
Large esophageal varices predict hepatocellular carcinoma in newly diagnosed cirrhosis: insights from machine learning and propensity score analysis
2026
·
Erica Villa
, Davide Guido
, et al.
·
Annals of Hepatology
·
1
PDF
Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma
2025
·
S. Ascari
, R. Chen
, et al.
·
Digestive and Liver Disease
·
1
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores
2026
·
Bernardo Stefanini
, Lorenza Rimassa
, et al.
·
Liver International
PDF
A snapshot on Aspergillus pulmonary diseases in Italy: a real-world study
2026
·
Mattia Nigro
, Emanuele Giardina
, et al.
·
European Respiratory Journal
Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score
2026
·
Lorenzo Canova
, Eleonora Alimenti
, et al.
·
Clinical Gastroenterology and Hepatology
THU-227-YI Predicting decompensation in unresectable hepatocellular carcinoma on immunotherapy: the ARTE score
2026
·
Lorenzo Canova
, Eleonora Alimenti
, et al.
·
Journal of Hepatology
Conversion to liver transplantation following atezolizumab-bevacizumab for HCC: the Bologna experience.
2025
·
B. Stefanini
, E. Prosperi
, et al.
·
Digestive and Liver Disease
A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease
2023
·
S. Ascari
, R. Sardone
, et al.
·
Digestive and Liver Disease
A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease
2023
·
Sara Ascari
, Rodolfo Sardone
, et al.
·
Journal of Hepatology
GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction of hepatocellular carcinoma (HCC) development in patients with compensated advanced chronic liver disease (cACLD): a 12-year prospective study
2023
·
Valentina Baldaccini
, Sara Ascari
, et al.
·
Journal of Hepatology
Il delirium nell’anziano
1998
·
Gianfranco Salvioli
, Chiara Mussi
, et al.
·
IRIS UNIMORE (University of Modena and Reggio Emilia)
Show more works
View as search
Works count:
14
Citation count:
36
H-index:
3
I10-index:
1
Year
Topic
Type